Inventor

Jason Pinkstaff

Inventor
Encinitas, CA, US

Overview

22→
Patents
2008–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 22 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides25%
A61KPreparations for medical, dental or toiletry purposes23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
C12NMicroorganisms or enzymes15%
Y02ATechnologies for adaptation to climate change14%
C07DHeterocyclic compounds2%
PatentTitleYear
10,961,291Modified FGF-21 polypeptides and their uses202110,954,270Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives202110,751,391Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid202010,702,588Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain202010,377,805Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses201910,253,083Therapeutic uses of modified relaxin polypeptides201910,208,123Anti-CD70 antibody drug conjugates20199,975,936Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids20189,962,450Method of treating heart failure with modified relaxin polypeptides20189,938,333Modified leptin polypeptides and their uses20189,796,754'Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives'20179,567,386'Therapeutic uses of modified relaxin polypeptides'20179,517,273'Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids'20169,452,222'Nucleic acids encoding modified relaxin polypeptides'20169,079,971'Modified FGF-21 polypeptides comprising non-naturally occurring amino acids'20158,735,539'Relaxin polypeptides comprising non-naturally encoded amino acids'20148,691,940'Relaxin polypeptides comprising non-naturally encoded amino acids'20148,383,365'Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives'20138,329,869'Modified interferon beta polypeptides and their uses'20128,114,630'Modified interferon beta polypeptides and their uses'20128,012,931'Modified FGF-21 polypeptides and their uses'20117,468,275'Synthetic internal ribosome entry sites and methods of identifying same'2008

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2008Based in Cardiff, CA, US· patent location history
2011–2021Patents assigned to AMBRX INC (20)· patent assignee history
2011–2020Based in Encinitas, CA, US· patent location history
2012–2018Patents assigned to KRAYNOV VADIM (6)· patent assignee history
2012–2018Patents assigned to PINKSTAFF JASON (6)· patent assignee history
2012–2018Patents assigned to KNUDSEN NICK (5)· patent assignee history
2012–2013Patents assigned to HAYS PUTNAM ANNA-MARIA A (3)· patent assignee history
2016–2021Based in San Rafael, CA, US· patent location history
2021Based in Carlsbad, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
AMBRX INC202011–2021
KRAYNOV VADIM62012–2018
PINKSTAFF JASONself62012–2018
KNUDSEN NICK52012–2018
HAYS PUTNAM ANNA-MARIA A32012–2013
Locations
LocationPatentsSpan
Encinitas, California, US162011–2020
San Rafael, California, US42016–2021
Carlsbad, California, US12021
Cardiff, California, US12008